(Total Views: 610)
Posted On: 09/14/2020 11:59:09 PM
Post# of 72446
I just read through the 10k. A couple of observations:
1) An increase in Outstanding Shares from 329M 6/30/20 to 343M as of 9/14/20 isn’t much of an increase. Leo is carefully managing cash and minimizing dilution.
2) Cash on hand was $6M as of 6/30/20 and now $6.4M as of 9/14/20. The budget from 6/30/20 to 6/30/21 is $8.2M per page 48. $6.2M of that $8.2M is for clinical trials. That tells me that Leo will not have to dilute much to run both the Q4 B-CV19 trial and the B-IBD UC trial 1st half 2021. Obviously any Government Grant funding would eliminate the need to dilute and could possibly move up the B-IBD UC trial and/or provide enough resources to initiate a B-OM phase3 trial.
3) B-IBD UC slipping into 1st half 2021 is most likely due to delays in all FDA trials that are not COVID related. This trial and the B-CV19 in Q4 are IMO the 2 key milestones that if successful will be extreme wealth builders for IPIX investors.
1) An increase in Outstanding Shares from 329M 6/30/20 to 343M as of 9/14/20 isn’t much of an increase. Leo is carefully managing cash and minimizing dilution.
2) Cash on hand was $6M as of 6/30/20 and now $6.4M as of 9/14/20. The budget from 6/30/20 to 6/30/21 is $8.2M per page 48. $6.2M of that $8.2M is for clinical trials. That tells me that Leo will not have to dilute much to run both the Q4 B-CV19 trial and the B-IBD UC trial 1st half 2021. Obviously any Government Grant funding would eliminate the need to dilute and could possibly move up the B-IBD UC trial and/or provide enough resources to initiate a B-OM phase3 trial.
3) B-IBD UC slipping into 1st half 2021 is most likely due to delays in all FDA trials that are not COVID related. This trial and the B-CV19 in Q4 are IMO the 2 key milestones that if successful will be extreme wealth builders for IPIX investors.
(10)
(0)
